drugset / Trial / NCT00848523

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

NCT00848523

Phase 2 Terminated 6 enrolled Neurological Surgery, P.C.
NaSingle-groupOpen-label

Summary

The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). It belongs to a new class of drugs called "histone deacetylase inhibitors." Histones are proteins located in the nucleus of cells that bind to DNA, the chemical that makes up genes. These proteins help control which genes are turned "on" and "off." Studies have shown that drugs like panobinostat (LBH589) may lead to tumor cell death.

Timeline

Start
2008-11
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 30 mg Oral

Indications